Caishuang Pang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caishuang Pang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Liwei Ren
Chongqing Medical University, Chongqing, China
1 shared publicationQingtao Hou
Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication- Qingtao Hou
Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication - Yingxiao Zhang
Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
1 shared publication - Yuqin Chen
Neuroscience Research Center, College of Basic Medicine, Chongqing Medical University, Chongqing, People’s Republic of China
1 shared publication Zhaowei Yang
Chongqing Medical University, Chongqing, China
1 shared publication
Latest Publications
- 30 November 2022
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (3) , 459-469
Comparative Muscle Tolerability of Different Types and Intensities of Statins: A Network Meta-Analysis of Double-Blind Randomized Controlled Trials
Purpose The benefits of statins for ischemic cardio-cerebrovascular diseases are well known. However, concerns around muscle adverse events still exist. We therefore aimed to compare the muscle safety of individual statins in adults. Methods PubMed, Embase, Cochrane Central Register of Controlled Trials and Web of Science were searched to include double-blind randomized controlled trials (RCTs) comparing one statin with another or with control treatment. Pairwise meta-analyses and network meta-analyses were undertaken with Stata 14.0 software. Relative risk (RR) with 95% confidence intervals (CIs) was adopted for each outcome. Results A total of 83 RCTs were included. In the pairwise meta-analysis, statins were significantly associated with only a slight increase in muscle symptoms compared with control (RR=1.05; 95% CI=1.01–1.09). In the drug-level network meta-analyses, no statistically significant difference was found between individual statins in the incidence of muscle symptoms, myalgia, myopathy, rhabdomyolysis, creatine kinase (CK) >10 times the upper limit of normal (ULN) or discontinuation due to muscle adverse events. In the dose-level network meta-analyses, there were no statistically significant dose-dependent effects on any outcomes except that moderate-intensity statins had a higher incidence of muscle symptoms than control (RR=1.13; 95% CI=1.01–1.27). Moderate simvastatin (RR=6.57; 95% CI=1.26–34.41) and moderate pravastatin (RR=5.96; 95% CI=1.00–35.44) had a statistically significantly higher incidence of CK >10×ULN compared with moderate atorvastatin. Lipophilic statins and statins metabolized by liver cytochrome P450 3A4 were not associated with an increased risk of muscle adverse events. Conclusion Statins may be generally safe on muscle. Moderate atorvastatin may be superior to equivalent simvastatin and pravastatin in muscle tolerability.
- 30 November 2022
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (3) , 459-469
Comparative Muscle Tolerability of Different Types and Intensities of Statins: A Network Meta-Analysis of Double-Blind Randomized Controlled Trials
Purpose The benefits of statins for ischemic cardio-cerebrovascular diseases are well known. However, concerns around muscle adverse events still exist. We therefore aimed to compare the muscle safety of individual statins in adults. Methods PubMed, Embase, Cochrane Central Register of Controlled Trials and Web of Science were searched to include double-blind randomized controlled trials (RCTs) comparing one statin with another or with control treatment. Pairwise meta-analyses and network meta-analyses were undertaken with Stata 14.0 software. Relative risk (RR) with 95% confidence intervals (CIs) was adopted for each outcome. Results A total of 83 RCTs were included. In the pairwise meta-analysis, statins were significantly associated with only a slight increase in muscle symptoms compared with control (RR=1.05; 95% CI=1.01–1.09). In the drug-level network meta-analyses, no statistically significant difference was found between individual statins in the incidence of muscle symptoms, myalgia, myopathy, rhabdomyolysis, creatine kinase (CK) >10 times the upper limit of normal (ULN) or discontinuation due to muscle adverse events. In the dose-level network meta-analyses, there were no statistically significant dose-dependent effects on any outcomes except that moderate-intensity statins had a higher incidence of muscle symptoms than control (RR=1.13; 95% CI=1.01–1.27). Moderate simvastatin (RR=6.57; 95% CI=1.26–34.41) and moderate pravastatin (RR=5.96; 95% CI=1.00–35.44) had a statistically significantly higher incidence of CK >10×ULN compared with moderate atorvastatin. Lipophilic statins and statins metabolized by liver cytochrome P450 3A4 were not associated with an increased risk of muscle adverse events. Conclusion Statins may be generally safe on muscle. Moderate atorvastatin may be superior to equivalent simvastatin and pravastatin in muscle tolerability.
- 26 May 2021
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 9 (4) , 341-351
Chest computed tomography as a primary tool in COVID-19 detection: an update meta-analysis
Purpose A growing number of publications have paid close attention to the chest computed tomography (CT) detection of COVID-19 with inconsistent diagnostic accuracy, the present meta-analysis assessed the available evidence regarding the overall performance of chest CT for COVID-19. Methods 2 × 2 diagnostic table was extracted from each of the included studies. Data on specificity (SPE), sensitivity (SEN), negative likelihood ratio (LR−), positive likelihood ratio (LR+), and diagnostic odds ratio (DOR) were calculated purposefully. Results Fifteen COVID-19 related publications met our inclusion criteria and were judged qualified for the meta-analysis. The following were summary estimates for diagnostic parameters of chest CT for COVID-19: SPE, 0.49 (95% CI 46–52%); SEN, 0.94 (95% CI 93–95%); LR−, 0.15 (95% CI 11–20%); LR+, 1.93 (95% CI 145–256%); DOR, 17.14 (95% CI 918–3199%); and the area under the receiver operating characteristic curve (AUC), 0.93. Conclusion Chest CT has high SEN, but the SPE is not ideal. It is highly recommended to use a combination of different diagnostic tools to achieve sufficient SEN and SPE. It should be taken into account as a diagnostic tool for current COVID-19 detection, especially for patients with symptoms.
- 26 May 2021
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 9 (4) , 341-351
Chest computed tomography as a primary tool in COVID-19 detection: an update meta-analysis
Purpose A growing number of publications have paid close attention to the chest computed tomography (CT) detection of COVID-19 with inconsistent diagnostic accuracy, the present meta-analysis assessed the available evidence regarding the overall performance of chest CT for COVID-19. Methods 2 × 2 diagnostic table was extracted from each of the included studies. Data on specificity (SPE), sensitivity (SEN), negative likelihood ratio (LR−), positive likelihood ratio (LR+), and diagnostic odds ratio (DOR) were calculated purposefully. Results Fifteen COVID-19 related publications met our inclusion criteria and were judged qualified for the meta-analysis. The following were summary estimates for diagnostic parameters of chest CT for COVID-19: SPE, 0.49 (95% CI 46–52%); SEN, 0.94 (95% CI 93–95%); LR−, 0.15 (95% CI 11–20%); LR+, 1.93 (95% CI 145–256%); DOR, 17.14 (95% CI 918–3199%); and the area under the receiver operating characteristic curve (AUC), 0.93. Conclusion Chest CT has high SEN, but the SPE is not ideal. It is highly recommended to use a combination of different diagnostic tools to achieve sufficient SEN and SPE. It should be taken into account as a diagnostic tool for current COVID-19 detection, especially for patients with symptoms.